New Data: Deucravacitinib Maintains Treatment Outcomes in PsO at Three Years
Psoriasis patients taking deucravacitinib (Sotyktu, BMS) once daily sustained results over a three-year period,according to long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials presented at the American Academy of Dermatology’s annual meeting in San Diego, CA. For the study, patients were randomized 1:2:1 to oral placebo, deucravacitinib 6mg once daily, or apremilast 30mg […]